News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Epigenomics AG  / Key word(s): Corporate Action

19.12.2013 09:40

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Berlin, Germany, December 19, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces the successful placement of convertible bonds, which the
Company's Executive Board, with approval of the Supervisory Board, resolved
to offer on December 3, 2013. 25 convertible bonds with an aggregate
principal amount of EUR 2,675,000.00, convertible into up to 2,675,000
shares of the Company's common stock have been placed successfully. The
details of this financing have been announced by way of ad hoc
notifications dated December 3 and December 13, 2013. The issuance of the
convertible bonds will generate gross proceeds of EUR 2,500,000.00.

The Bonds will be convertible into 107,000 shares of Epigenomics' common
stock at any time during their term against payment of a conversion premium
amounting to EUR 521,090.00, equaling a conversion price of EUR 5.87. In
the event of a conversion of all 25 Bonds against payment of the conversion
premium, the Company may generate further gross proceeds of up to EUR
13,027,250.00. Alternatively, after August 1, 2014, each Bond will be
redeemable upon request of the bondholder at its principal amount of EUR
107,000.00. Upon maturity of the Bonds or upon FDA approval of its lead
product Epi proColon(R), on certain conditions, Epigenomics is entitled to
require mandatory conversion. The complete Terms and Conditions are
available on Epigenomics' website under

Epigenomics expects that the gross proceeds from the issuance of the Bonds
will contribute to securing the funding of the operating business beyond
the FDA approval of the Company's lead product, Epi proColon(R), a
blood-based test for the detection of colorectal cancer. Among others,
Epigenomics, hereby, intends to fund preparatory activities for the test's
introduction onto the U.S.-American market.

- End of Ad hoc -

Contact Epigenomics AG

Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386

Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.

19.12.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and

Language:     English
Company:      Epigenomics AG
              Kleine Präsidentenstraße 1
              10178 Berlin
Phone:        +49 30 24345-0
Fax:          +49 30 24345-555
ISIN:         DE000A1K0516
WKN:          A1K051  
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Stuttgart
End of Announcement                             DGAP News-Service